E14a2 BCR-ABL1 transcript is associated with a higher rate of treatment-free remission in individuals with chronic myeloid leukemia after stopping tyrosine kinase inhibitor therapy

被引：41
|
作者：
Claudiani, Simone [1 ]
Apperley, Jane F. [1 ]
Gale, Robert Peter [1 ]
Clark, Richard [2 ]
Szydlo, Richard [1 ]
Deplano, Simona [1 ]
Palanicawandar, Renuka [1 ]
Khorashad, Jamshid [1 ]
Foroni, Letizia [1 ]
Milojkovic, Dragana [1 ]
机构：
[1] Imperial Coll Healthcare NHS Trust, Hammersmith Hosp, Dept Haematol, London, England
[2] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England
来源：
HAEMATOLOGICA | 2017年 / 102卷 / 08期
关键词：
CHRONIC MYELOGENOUS LEUKEMIA; MOLECULAR RESPONSE; YOUNG-ADULTS; IMATINIB; E13A2; TRIAL;
D O I：
10.3324/haematol.2017.168740
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E297 / E299
页数：3
相关论文
共 50 条
  • [1] Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
    Claudiani, Simone
    Apperley, Jane F.
    Khan, Afzal
    Khorashad, Jamshid
    Milojkovic, Dragana
    HAEMATOLOGICA, 2020, 105 (05) : E225 - E227
  • [2] e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response
    Marce, Silvia
    Mendez, Aleix
    Xicoy, Blanca
    Estrada, Natalia
    Cabezon, Marta
    Sturla, Antonella Luciana
    Garcia, Miriam Ratia
    Angona, Anna
    Amat, Paula
    Escribano Serrat, Silvia
    Scalzulli, Emilia
    Morgades, Mireia
    Senin, Alicia
    Hernandez-Boluda, Juan Carlos
    Ferrer-Marin, Francisca
    Anguita, Eduardo
    Cortes, Montserrat
    Plensa, Esther
    Breccia, Massimo
    Garcia-Gutierrez, Valentin
    Zamora, Lurdes
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (03)
  • [3] Early BCR-ABL1 Transcript Decline after 1 Month of Tyrosine Kinase Inhibitor Therapy as an Indicator for Treatment Response in Chronic Myeloid Leukemia
    El Missiry, Mohamed
    Hjorth-Hansen, Henrik
    Richter, Johan
    Olson-Stromberg, Ulla
    Stenke, Leif
    Porkka, Kimmo
    Kreutzman, Anna
    Mustjoki, Satu
    PLOS ONE, 2017, 12 (01):
  • [4] Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib
    Marce, Silvia
    Xicoy, Blanca
    Garcia, Olga
    Cabezon, Marta
    Estrada, Natalia
    Velez, Patricia
    Boque, Concepcion
    Sagues, Miguel
    Angona, Anna
    Teruel-Montoya, Raul
    Ferrer-Marin, Francisca
    Amat, Paula
    Hernandez-Boluda, Juan Carlos
    Ibarra, Mariana M.
    Anguita, Eduardo
    Cortes, Montserrat
    Fernandez-Ruiz, Andres
    Fontanals, Sandra
    Zamora, Lurdes
    JOURNAL OF CLINICAL MEDICINE, 2021, 10 (14)
  • [5] Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Pinilla-Ibarz, Javier
    Sweet, Kendra
    Emole, Josephine
    Fradley, Michael
    ANTICANCER RESEARCH, 2015, 35 (12) : 6355 - 6364
  • [6] The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients with Chronic Myeloid Leukemia
    Ercaliskan, Abdulkadir
    Eskazan, A. Emre
    CANCER, 2018, 124 (19) : 3806 - 3818
  • [7] BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
    Cuellar, Sandra
    Vozniak, Michael
    Rhodes, Jill
    Forcello, Nicholas
    Olszta, Daniel
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2018, 24 (06) : 433 - 452
  • [8] BCR-ABL1 transcript doubling time as a predictor for treatment-free remission failure after imatinib discontinuation in chronic myeloid leukaemia in chronic phase
    Hwan Kim, Dennis Dong
    Simon Kim, Taehyung
    Atenafu, Eshetu G.
    Novitzky Basso, Igor
    Forrest, Donna
    Bence-Bruckler, Isabelle
    Savoie, Lynn
    Busque, Lambert
    Keating, Mary-Margaret
    Delage, Robert
    Xenocostas, Anargyros
    Liew, Elena
    Paulson, Kristjan
    Stockley, Tracy
    Laneuville, Pierre
    Lipton, Jeffrey H.
    Kamel-Reid, Suzanne
    Leber, Brian
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (01) : 136 - 145
  • [9] Effect of BCR::ABL1 transcript type and droplet digital polymerase chain reaction on successful treatment-free remission in chronic myeloid leukemia patients who discontinued tyrosine kinase inhibitor
    Park, Hyunkyung
    Kim, Hyeong-Joon
    Sohn, Sang-Kyun
    Baik, Yoonsuk
    Kim, Dongho
    Lee, Sung-Yeoun
    Kong, Jee Hyun
    Kim, Hawk
    Shin, Dong-Yeop
    Ahn, Jae-Sook
    Park, Jinny
    Park, Seonyang
    Kim, Inho
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2023, 14
  • [10] Intracranial hypertension associated with BCR-ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia
    Haddad, Fadi
    Kantarjian, Hagop
    Issa, Ghayas C.
    Jabbour, Elias
    Sasaki, Koji
    LEUKEMIA & LYMPHOMA, 2022, 63 (07) : 1714 - 1717
12345